Glenmark Pharma to launch birth control pill in USA

Glenmark Pharmaceuticals said it got the approval of the United States Food & Drug Administration to launch a generic version of birth control pill Loestrin from Allergan Pharmaceuticals International.

The drug had annual sales of approximately $116.8 million.

The drug Norethindrone Acetate and Ethinyl Estradiol Tablets will be sold in the 1/20 dosage.

Glenmark’s current portfolio consists of 129 products authorized for distribution in the U.S. marketplace and 58 generic applications pending approval with the U.S. FDA.

“In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” it said.